IDEAS home Printed from https://ideas.repec.org/a/spr/eujhec/v15y2014i8p791-800.html
   My bibliography  Save this article

The impact of memantine in combination with acetylcholinesterase inhibitors on admission of patients with Alzheimer’s disease to nursing homes: cost-effectiveness analysis in France

Author

Listed:
  • Jacques Touchon
  • Jean Lachaine
  • Catherine Beauchemin
  • Anna Granghaud
  • Benoit Rive
  • Sébastien Bineau

Abstract

The costs associated with the care of Alzheimer’s disease patients are very high, particularly those associated with nursing home placement. The combination of a cholinesterase inhibitor (ChEI) and memantine has been shown to significantly delay admission to nursing homes as compared to treatment with a ChEI alone. The objective of this cost-effectiveness analysis was to evaluate the economic impact of the concomitant use of memantine and ChEI compared to ChEI alone. Markov modelling was used in order to simulate transitions over time among three discrete health states (non-institutionalised, institutionalised and deceased). Transition probabilities were obtained from observational studies and French national statistics, utilities from a previous US survey and costs from French national statistics. The analysis was conducted from societal and healthcare system perspectives. Mean time to nursing home admission was 4.57 years for ChEIs alone and 5.54 years for combination therapy, corresponding to 0.98 additional years, corresponding to a gain in quality adjusted life years (QALYs) of 0.25. From a healthcare system perspective, overall costs were €98,609 for ChEIs alone and €90,268 for combination therapy, representing cost savings of €8,341. From a societal perspective, overall costs were €122,039 and €118,721, respectively, representing cost savings of €3,318. Deterministic and probabilistic (Monte Carlo simulations) sensitivity analyses indicated that combination therapy would be the dominant strategy in most scenarios. In conclusion, combination therapy with memantine and a ChEI is a cost-saving alternative compared to ChEI alone as it is associated with lower cost and increased QALYs from both a societal and a healthcare perspective. Copyright The Author(s) 2014

Suggested Citation

  • Jacques Touchon & Jean Lachaine & Catherine Beauchemin & Anna Granghaud & Benoit Rive & Sébastien Bineau, 2014. "The impact of memantine in combination with acetylcholinesterase inhibitors on admission of patients with Alzheimer’s disease to nursing homes: cost-effectiveness analysis in France," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(8), pages 791-800, November.
  • Handle: RePEc:spr:eujhec:v:15:y:2014:i:8:p:791-800
    DOI: 10.1007/s10198-013-0523-y
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.1007/s10198-013-0523-y
    Download Restriction: Access to full text is restricted to subscribers.

    File URL: https://libkey.io/10.1007/s10198-013-0523-y?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Denis Getsios & Kristen Migliaccio-Walle & Jaime Caro, 2007. "NICE Cost-Effectiveness Appraisal of Cholinesterase Inhibitors," PharmacoEconomics, Springer, vol. 25(12), pages 997-1006, December.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. L. M. Peña-Longobardo & B. Rodríguez-Sánchez & J. Oliva-Moreno & I. Aranda-Reneo & J. López-Bastida, 2019. "How relevant are social costs in economic evaluations? The case of Alzheimer’s disease," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(8), pages 1207-1236, November.
    2. Mark Belger & Josep Maria Haro & Catherine Reed & Michael Happich & Josep Maria Argimon & Giuseppe Bruno & Richard Dodel & Roy W. Jones & Bruno Vellas & Anders Wimo, 2019. "Determinants of time to institutionalisation and related healthcare and societal costs in a community-based cohort of patients with Alzheimer’s disease dementia," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(3), pages 343-355, April.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Eric Stallard & Bruce Kinosian & Arthur S. Zbrozek & Anatoliy I. Yashin & Henry A. Glick & Yaakov Stern, 2010. "Estimation and Validation of a Multiattribute Model of Alzheimer Disease Progression," Medical Decision Making, , vol. 30(6), pages 625-638, November.
    2. Denis Getsios & Steve Blume & K. Ishak & Grant Maclaine, 2010. "Cost Effectiveness of Donepezil in the Treatment of Mild to Moderate Alzheimer’s Disease," PharmacoEconomics, Springer, vol. 28(5), pages 411-427, May.
    3. Dixon, Josie & Ferdinand, Monique & D'Amico, Francesco & Knapp, Martin, 2015. "Exploring the cost-effectiveness of a one-off screen for dementia (for people aged 75 years in England and Wales)," LSE Research Online Documents on Economics 58109, London School of Economics and Political Science, LSE Library.
    4. Kristin Kahle-Wrobleski & Howard Fillit & Jonathan Kurlander & Catherine Reed & Mark Belger, 2015. "Methodological challenges in assessing the impact of comorbidities on costs in Alzheimer’s disease clinical trials," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(9), pages 995-1004, December.

    More about this item

    Keywords

    Alzheimer’s disease; Cholinesterase inhibitors; Memantine; Cost-effectiveness; Nursing home admission; D61; I10; I12; I18;
    All these keywords.

    JEL classification:

    • D61 - Microeconomics - - Welfare Economics - - - Allocative Efficiency; Cost-Benefit Analysis
    • I10 - Health, Education, and Welfare - - Health - - - General
    • I12 - Health, Education, and Welfare - - Health - - - Health Behavior
    • I18 - Health, Education, and Welfare - - Health - - - Government Policy; Regulation; Public Health

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:eujhec:v:15:y:2014:i:8:p:791-800. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.